公开(公告)号：US20200237920A1

公开(公告)日：2020-07-30

申请号：US16851779

申请日：2020-04-17

申请人： EVANGELOS KARAVAS ,  EFTHIMIOS KOUTRIS ,  DIMITRIOS BIKIARIS ,  SOTIRIA CHATIDOU ,  AMALIA DIAKIDOU ,  PANAGIOTIS BARMPALEXIS ,  LOUIZA KONSTANTI ,  KATERINA MINIOTI

发明人： EVANGELOS KARAVAS ,  EFTHIMIOS KOUTRIS ,  DIMITRIOS BIKIARIS ,  SOTIRIA CHATIDOU ,  AMALIA DIAKIDOU ,  PANAGIOTIS BARMPALEXIS ,  LOUIZA KONSTANTI ,  KATERINA MINIOTI

IPC分类号： A61K47/38 ,  A61K31/5377 ,  A61K9/00 ,  A61K9/70 ,  A61K31/675 ,  A61K47/14 ,  A61K47/34 ,  A61K47/44 ,  A61K47/46

摘要： The present invention relates to a controlled release sterile injectable formulation in the form of solution, suspension or sol-gel formulation for intramuscular or subcutaneous administration comprising a therapeutically effective amount of a neurokinin 1 receptor antagonist, in particular Aprepitant or Fosaprepitant or pharmaceutical acceptable salt, derivative or metabolite thereof. It also relates to a process for developing such formulations.

公开(公告)号：US20150165045A1

公开(公告)日：2015-06-18

申请号：US14412147

申请日：2012-07-06

申请人： Evangelos Karavas ,  Efthimios Koutris ,  Dimitrios Bikiaris ,  Sotiria Chatidou ,  Amalia Diakidou ,  Panagiotis Barmpalexis ,  Louiza Konstanti ,  Katerina Minioti

发明人： Evangelos Karavas ,  Efthimios Koutris ,  Dimitrios Bikiaris ,  Sotiria Chatidou ,  Amalia Diakidou ,  Panagiotis Barmpalexis ,  Louiza Konstanti ,  Katerina Minioti

IPC分类号： A61K47/38 ,  A61K31/675 ,  A61K47/34 ,  A61K47/44 ,  A61K47/14 ,  A61K47/46 ,  A61K31/5377 ,  A61K9/00

CPC分类号： A61K47/38 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/7015 ,  A61K31/5377 ,  A61K31/675 ,  A61K47/14 ,  A61K47/34 ,  A61K47/44 ,  A61K47/46

摘要： The present invention relates to a controlled release sterile injectable formulation in the form of solution, suspension or sol-gel formulation for intramuscular or subcutaneous administration comprising a therapeutically effective amount of a neurokinin 1 receptor antagonist, in particular Aprepitant or Fosaprepitant or pharmaceutical acceptable salt, derivative or metabolite thereof. It also relates to a process for developing such formulations.

摘要翻译： 本发明涉及用于肌内或皮下给药的溶液，悬浮液或溶胶 - 凝胶制剂形式的控释免疫可注射制剂，其包含治疗有效量的神经激肽1受体拮抗剂，特别是阿维菌素或福沙吡啶或药学上可接受的盐， 衍生物或代谢物。 它还涉及开发这种制剂的方法。